In this review, we will discuss the clinical implications of the correlation between PD-1/PD-L1 and PI3K/AKT/mTOR pathway activation in the progression and treatment of NSCLC, and explore the current situation of relevant targeted drugs and immunotherapy for NSCLC. This evidence concerns the gene MTOR and non-small cell lung carcinoma.